These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17853268)

  • 1. Bilateral ankle oedema in a patient taking escitalopram.
    Masdrakis VG; Oulis P; Kouzoupis AV; Masdrakis GV; Soldatos CR
    World J Biol Psychiatry; 2009; 10(4 Pt 3):939-41. PubMed ID: 17853268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escitalopram-Associated Recurrent Sinusitis: A Case Report.
    Yesilkaya UH; Sen M
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):347-349. PubMed ID: 33657068
    [No Abstract]   [Full Text] [Related]  

  • 3. Delirium during i. v. citalopram treatment: a case report.
    Delić M; Pregelj P
    Pharmacopsychiatry; 2013 Jan; 46(1):37-8. PubMed ID: 22821385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
    Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
    J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.
    Clayton A; Kornstein S; Prakash A; Mallinckrodt C; Wohlreich M
    J Sex Med; 2007 Jul; 4(4 Pt 1):917-29. PubMed ID: 17627739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
    Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
    Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syndrome of inappropriate antidiuretic hormone associated with escitalopram therapy.
    Nirmalani A; Stock SL; Catalano G
    CNS Spectr; 2006 Jun; 11(6):429-32. PubMed ID: 16816780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escitalopram.
    Aronson S; Delgado P
    Drugs Today (Barc); 2004 Feb; 40(2):121-31. PubMed ID: 15045034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of hyponatremia associated with escitalopram.
    Nahshoni E; Weizman A; Shefet D; Pik N
    J Clin Psychiatry; 2004 Dec; 65(12):1722. PubMed ID: 15641882
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
    Kennedy SH; Andersen HF; Lam RW
    J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram.
    Jacobsen PL; Nomikos GG; Zhong W; Cutler AJ; Affinito J; Clayton A
    CNS Spectr; 2020 Feb; 25(1):50-63. PubMed ID: 31010445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
    Burke WJ; Gergel I; Bose A
    J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unfavorable smell with citalopram?
    Ghanizadeh A
    J Clin Psychopharmacol; 2007 Oct; 27(5):528-9. PubMed ID: 17873697
    [No Abstract]   [Full Text] [Related]  

  • 15. Serotonin syndrome associated with the use of escitalopram.
    Huska MT; Catalano G; Catalano MC
    CNS Spectr; 2007 Apr; 12(4):270-4. PubMed ID: 17426664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of the electroconvulsive therapy-escitalopram combination.
    Masdrakis VG; Oulis P; Florakis A; Valamoutopoulos T; Markatou M; Papadimitriou GN
    J ECT; 2008 Dec; 24(4):289-91. PubMed ID: 18617866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to SSRI-induced enuresis: a case report.
    Ibrahim Ramadan M; Khan AY; Weston WE
    J Clin Psychopharmacol; 2006 Feb; 26(1):98-9. PubMed ID: 16415720
    [No Abstract]   [Full Text] [Related]  

  • 18. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
    Miner CM; Brown EB; Gonzales JS; Munir R
    J Clin Psychiatry; 2002 Mar; 63(3):232-40. PubMed ID: 11926723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agomelatine reversal of escitalopram-induced apathy: a case report.
    De Berardis D; Valchera A; Fornaro M; Serroni N; Marini S; Moschetta FS; Martinotti G; Di Giannantonio M
    Psychiatry Clin Neurosci; 2013 Apr; 67(3):190-1. PubMed ID: 23581873
    [No Abstract]   [Full Text] [Related]  

  • 20. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
    Lam RW; Lönn SL; Despiégel N
    Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.